To that end, we performed a post hoc descriptive analysis of SIMPLIFY-2 focused on patient subgroups for whom anemia management is a key consideration: (1) patients with moderate-to-severe anemia, defined by baseline Hb of < 100 g/L, and (2) patients who were not transfusion independent (TI) at baseline. The gene discussed is GSTM1; the disease is anemia (phenotype).